Literature DB >> 12972574

Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation.

Geraldine Ferjoux1, Frederic Lopez, Jean-Pierre Esteve, Audrey Ferrand, Eric Vivier, Frederic Vely, Nathalie Saint-Laurent, Lucien Pradayrol, Louis Buscail, Christiane Susini.   

Abstract

The G protein-coupled sst2 somatostatin receptor acts as a negative cell growth regulator. Sst2 transmits antimitogenic signaling by recruiting and activating the tyrosine phosphatase SHP-1. We now identified Src and SHP-2 as sst2-associated molecules and demonstrated their role in sst2 signaling. Surface plasmon resonance and mutation analyses revealed that SHP-2 directly associated with phosphorylated tyrosine 228 and 312, which are located in sst2 ITIMs (immunoreceptor tyrosine-based inhibitory motifs). This interaction was required for somatostatin-induced SHP-1 recruitment and activation and consequent inhibition of cell proliferation. Src interacted with sst2 and somatostatin promoted a transient Gbetagamma-dependent Src activation concomitant with sst2 tyrosine hyperphosphorylation and SHP-2 activation. These steps were abrogated with catalytically inactive Src. Both catalytically inactive Src and SHP-2 mutants abolished somatostatin-induced SHP-1 activation and cell growth inhibition. Sst2-Src-SHP-2 complex formation was dynamic. Somatostatin further induced sst2 tyrosine dephosphorylation and complex dissociation accompanied by Src and SHP-2 inhibition. These steps were defective in cells expressing a catalytically inactive Src mutant. All these data suggest that Src acts upstream of SHP-2 in sst2 signaling and provide evidence for a functional role for Src and SHP-2 downstream of an inhibitory G protein-coupled receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12972574      PMCID: PMC196590          DOI: 10.1091/mbc.e03-02-0069

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  68 in total

Review 1.  Regulation of immune responses through inhibitory receptors.

Authors:  E O Long
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

2.  Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2.

Authors:  J M Cunnick; L Mei; C A Doupnik; J Wu
Journal:  J Biol Chem       Date:  2001-04-25       Impact factor: 5.157

3.  Fyn kinase-directed activation of SH2 domain-containing protein-tyrosine phosphatase SHP-2 by Gi protein-coupled receptors in Madin-Darby canine kidney cells.

Authors:  H Tang; Z J Zhao; X Y Huang; E J Landon; T Inagami
Journal:  J Biol Chem       Date:  1999-04-30       Impact factor: 5.157

4.  sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1.

Authors:  P Pagès; N Benali; N Saint-Laurent; J P Estève; A V Schally; J Tkaczuk; N Vaysse; C Susini; L Buscail
Journal:  J Biol Chem       Date:  1999-05-21       Impact factor: 5.157

5.  Agonist-dependent interaction of the rat somatostatin receptor subtype 2 with cortactin-binding protein 1.

Authors:  H Zitzer; D Richter; H J Kreienkamp
Journal:  J Biol Chem       Date:  1999-06-25       Impact factor: 5.157

6.  Cyclic AMP-mediated inhibition of cell growth requires the small G protein Rap1.

Authors:  J M Schmitt; P J Stork
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

7.  The 64-kDa protein that associates with the platelet-derived growth factor receptor beta subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp.

Authors:  A Kazlauskas; G S Feng; T Pawson; M Valius
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

8.  Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains.

Authors:  S Pluskey; T J Wandless; C T Walsh; S E Shoelson
Journal:  J Biol Chem       Date:  1995-02-17       Impact factor: 5.157

9.  Cellular expression of the carboxyl terminus of a G protein-coupled receptor kinase attenuates G beta gamma-mediated signaling.

Authors:  W J Koch; B E Hawes; J Inglese; L M Luttrell; R J Lefkowitz
Journal:  J Biol Chem       Date:  1994-02-25       Impact factor: 5.157

10.  Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.

Authors:  L Buscail; N Delesque; J P Estève; N Saint-Laurent; H Prats; P Clerc; P Robberecht; G I Bell; C Liebow; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

View more
  19 in total

1.  The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinoma.

Authors:  N M Abdel-Hamid; O M Mohafez; M H Nazmy; A Farhan; K Thabet
Journal:  Environ Health Prev Med       Date:  2015-03-01       Impact factor: 3.674

Review 2.  Selective agonism in somatostatin receptor signaling and regulation.

Authors:  Agnes Schonbrunn
Journal:  Mol Cell Endocrinol       Date:  2007-10-07       Impact factor: 4.102

Review 3.  Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5.

Authors:  Stefan Schulz; Andreas Lehmann; Andrea Kliewer; Falko Nagel
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 4.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

5.  Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.

Authors:  Valeria Cambiaghi; Eleonora Vitali; Diego Morone; Erika Peverelli; Anna Spada; Giovanna Mantovani; Andrea Gerardo Lania
Journal:  Endocrine       Date:  2016-07-12       Impact factor: 3.633

6.  Somatostatin activates Ras and ERK1/2 via a G protein βγ-subunit-initiated pathway in thyroid cells.

Authors:  Francisco J Rodríguez-Álvarez; Eva Jiménez-Mora; María Caballero; Beatriz Gallego; Antonio Chiloeches; Ma José Toro
Journal:  Mol Cell Biochem       Date:  2015-10-16       Impact factor: 3.396

7.  Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway.

Authors:  Corinne Bousquet; Julie Guillermet-Guibert; Nathalie Saint-Laurent; Elodie Archer-Lahlou; Frédéric Lopez; Marjorie Fanjul; Audrey Ferrand; Daniel Fourmy; Carole Pichereaux; Bernard Monsarrat; Lucien Pradayrol; Jean-Pierre Estève; Christiane Susini
Journal:  EMBO J       Date:  2006-08-17       Impact factor: 11.598

8.  Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.

Authors:  Katja Kiseljak-Vassiliades; Mei Xu; Taylor S Mills; Elizabeth E Smith; Lori J Silveira; Kevin O Lillehei; Janice M Kerr; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Mol Cell Endocrinol       Date:  2015-09-21       Impact factor: 4.102

9.  A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin A negatively controls the PI3K pathway.

Authors:  Souad Najib; Nathalie Saint-Laurent; Jean-Pierre Estève; Stefan Schulz; Elisa Boutet-Robinet; Daniel Fourmy; Jens Lättig; Catherine Mollereau; Stéphane Pyronnet; Christiane Susini; Corinne Bousquet
Journal:  Mol Cell Biol       Date:  2011-12-27       Impact factor: 4.272

10.  Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer.

Authors:  Min Li; Xiaochi Wang; Wei Li; Fei Li; Hui Yang; Hao Wang; F Charles Brunicardi; Changyi Chen; Qizhi Yao; William E Fisher
Journal:  Cancer Sci       Date:  2008-09-22       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.